NF2 and non-small cell lung carcinoma: For instance, we characterized diverse resistance mechanisms occurring in patients with ALK-rearranged NSCLC progressing on the third-generation ALK inhibitor lorlatinib such as additional ALK secondary compound mutations, and NF2 loss of function mutations25.